好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2023 Annual Meeting | H337 - Lecanemab: A Practical Perspective (Practice and Policy Hub)

Thursday 04/27/23
01:30 PM - 02:00 PM EST Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Hubs (Practice and Policy)
Katherine Coerver, MD, PhD, FAAN
Practice, Policy, and Ethics
Participants should be able to understand and identify which patient population may benefit from the use of anti-amyloid therapy, describe the resources necessary to screen and monitor patients who may be receving anti-amyloid therapy, detail a potential work flow to help offices access patients while receiving therapy, and recognize the potential issues which may occur with use of these medications.
0.50 CME credit
Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism
Introductory
Business of Neurology
General Neurologist, Specialist Neurologist, Advanced Practice Provider
Didactic
Event Timeline
01:30 PM - 02:00 PM EST Speaker Lecanemab: A Practical Perspective
Katherine Coerver, MD, PhD, FAAN
Faculty Disclosures
Katherine Coerver, MD, PhD, FAAN Dr. Coerver has received personal compensation for serving as an employee of CenExel. Dr. Coerver has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai . Dr. Coerver has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ZS Associates. Dr. Coerver has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai . Dr. Coerver has received research support from Lilly. Dr. Coerver has received research support from Annovis. Dr. Coerver has received research support from Biogen. Dr. Coerver has received research support from AriBio. Dr. Coerver has received research support from Actinogen.